W
Winfried März
Researcher at Heidelberg University
Publications - 398
Citations - 46505
Winfried März is an academic researcher from Heidelberg University. The author has contributed to research in topics: Vitamin D and neurology & Genome-wide association study. The author has an hindex of 74, co-authored 361 publications receiving 36423 citations. Previous affiliations of Winfried März include University of Ulm & University of Graz.
Papers
More filters
Journal ArticleDOI
Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study
Nicolas Verheyen,Katharina Kienreich,Martin Gaksch,Adriana J. van Ballegooijen,Martin R. Grübler,Bríain ó Hartaigh,Bríain ó Hartaigh,Johannes Schmid,Astrid Fahrleitner-Pammer,Elisabeth Kraigher-Krainer,Caterina Colantonio,Evgeny Belyavskiy,Gerlies Treiber,Cristiana Catena,Helmut Brussee,Burkert Pieske,Burkert Pieske,Winfried März,Winfried März,Winfried März,Andreas Tomaschitz,Andreas Tomaschitz,Stefan Pilz,Stefan Pilz +23 more
TL;DR: Cross‐sectional data from the Styrian Hypertension Study suggest a direct interrelationship between PTH and nocturnal BP regulation, and whether lowering high PTH concentrations reduces the burden of high noCTurnal BP remains to be shown in future studies.
Journal ArticleDOI
Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease
Boris Schmitz,Marcus E. Kleber,Malte Lenders,Graciela E. Delgado,Christiane Engelbertz,Jie Huang,Hermann Pavenstädt,Günter Breithardt,Stefan-Martin Brand,Winfried März,Winfried März,Winfried März,Eva Brand +12 more
TL;DR: Genome-wide replication of rs139401390A > G in the Coronary Artery Disease and Renal Failure (CAD-REF) registry and comparison of genotypes for risk of reduced kidney function in the overall LURIC study revealed higher adjusted odds ratios for eGFR <60 ml/min/1.73 m2.
Journal ArticleDOI
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Nicolas Verheyen,Martin R. Grübler,Andreas Meinitzer,Christian Trummer,Verena Schwetz,Karin Amrein,H. P. Dimai,Winfried März,Cristiana Catena,Dirk von Lewinski,Jakob Voelkl,Ioana Alesutan,Astrid Fahrleitner-Pammer,Helmut Brussee,Stefan Pilz,Andreas Tomaschitz +15 more
TL;DR: Data provide first evidence from a randomized and placebo-controlled trial that short-term MR antagonism may not affect bone turnover, at least in patients with primary hyperparathyroidism.
Journal ArticleDOI
Association of Factor V Leiden with Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data
Bakhtawar K. Mahmoodi,Vinicius Tragante,Marcus E. Kleber,Michael V. Holmes,Michael V. Holmes,Amand F. Schmidt,Amand F. Schmidt,Raymond O McCubrey,Laurence J. Howe,Kenan Direk,Hooman Allayee,Ekaterina V Baranova,Peter S. Braund,Peter S. Braund,Graciela E. Delgado,Niclas Eriksson,Crystel M. Gijsberts,Yan Gong,Jaana Hartiala,Mahyar Heydarpour,Mahyar Heydarpour,Gerard Pasterkamp,Salma Kotti,Pekka Kuukasjärvi,Petra A. Lenzini,Daniel Levin,Leo-Pekka Lyytikäinen,Jochen D. Muehlschlegel,Jochen D. Muehlschlegel,Christopher P. Nelson,Christopher P. Nelson,Kjell Nikus,Anna P. Pilbrow,W.H. Wilson Tang,W.H. Wilson Tang,Sander W. van der Laan,Jessica van Setten,Ragnar O. Vilmundarson,John E. Deanfield,Panos Deloukas,Frank Dudbridge,Stefan James,Ify R. Mordi,Andrej Teren,Thomas O. Bergmeijer,Simon C. Body,Michiel L. Bots,Michiel L. Bots,Ralph Burkhardt,Rhonda M. Cooper-DeHoff,Sharon Cresci,Nicolas Danchin,Robert N. Doughty,Diederick E. Grobbee,Emil Hagström,Stanley L. Hazen,Stanley L. Hazen,Claes Held,Imo E. Hoefer,G. Kees Hovingh,Julie A. Johnson,Marcin P. Kaczor,Mika Kähönen,Olaf H. Klungel,Jari Laurikka,Terho Lehtimäki,Anke H. Maitland-van der Zee,Anke H. Maitland-van der Zee,Ruth McPherson,Colin N. A. Palmer,Adriaan O. Kraaijeveld,Carl J. Pepine,Marek Sanak,Naveed Sattar,Markus Scholz,Tabassome Simon,Tabassome Simon,John A. Spertus,Alexandre F.R. Stewart,Wojciech Szczeklik,Joachim Thiery,Frank L.J. Visseren,Johannes Waltenberger,A. Mark Richards,A. Mark Richards,Chim C. Lang,Vicky A. Cameron,Axel Åkerblom,Guillaume Paré,Guillaume Paré,Winfried März,Winfried März,Winfried März,Nilesh J. Samani,Nilesh J. Samani,Aroon D. Hingorani,Jurriën M. ten Berg,Lars Wallentin,Folkert W. Asselbergs,Folkert W. Asselbergs,Riyaz S. Patel,Riyaz S. Patel +101 more
TL;DR: Factor V Leiden was not associated with increased risk of subsequent atherothrombotic events and mortality in high-risk participants with established and treated CHD, and risk estimates for the secondary outcomes including stroke, coronary revascularization, cardiovascular mortality, and all-cause mortality were close to identity.
Journal ArticleDOI
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
Michael Müller,Carl-Ludwig Schönfeld,Tanja B. Grammer,Vera Krane,Christiane Drechsler,Bernd Genser,Thomas Kohnen,Christoph Wanner,Winfried März,Winfried März,Winfried März +10 more
TL;DR: The prevalence of DR in patients with type 2 diabetes mellitus requiring hemodialysis is higher than in patients suffering from T2DM, who do not receive hemodIALysis, and DR was positively related to systolic blood pressure (BP), glucometabolic control, and, paradoxically, HDL cholesterol.